# reload+after+2024-01-23 16:45:42.298854
address1§200 Arsenal Yards Boulevard
address2§Suite 230
city§Watertown
state§MA
zip§02472
country§United States
phone§857 285 5300
website§https://www.kymeratx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
fullTimeEmployees§192
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Bruce L. Booth DPHIL, Ph.D.', 'age': 49, 'title': 'Co-Founder & Chairman', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 79194, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nello  Mainolfi M.D., Ph.D.', 'age': 45, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 975200, 'exercisedValue': 4854512, 'unexercisedValue': 15595656}, {'maxAge': 1, 'name': 'Mr. Bruce N. Jacobs CFA', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'totalPay': 648303, 'exercisedValue': 2040913, 'unexercisedValue': 4241946}, {'maxAge': 1, 'name': 'Dr. Jared A. Gollob M.D.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 637808, 'exercisedValue': 463946, 'unexercisedValue': 4266092}, {'maxAge': 1, 'name': 'Dr. Jeremy G. Chadwick Ph.D.', 'age': 60, 'title': 'Chief Operating Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ellen V. Chiniara Esq., J.D.', 'age': 64, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen  Weisbach', 'title': 'Head of People & Culture', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Juliet  Williams B.A Ph.D.', 'title': 'Head of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.215
priceToSalesTrailing12Months§32.193733
currency§USD
dateShortInterest§1702598400
forwardEps§-3.2
pegRatio§-5.64
exchange§NGM
quoteType§EQUITY
shortName§Kymera Therapeutics, Inc.
longName§Kymera Therapeutics, Inc.
firstTradeDateEpochUtc§1598016600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fe087242-38df-325c-aac8-26165faa63ce
gmtOffSetMilliseconds§-18000000
targetHighPrice§103.0
targetLowPrice§16.0
targetMeanPrice§39.71
targetMedianPrice§32.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§14
quickRatio§5.725
grossMargins§-2.8262398
ebitdaMargins§0.0
trailingPegRatio§None
